ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1899

Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States

Jinoos Yazdany1, April Jorge2, Claire Barber3, April Barnado4, Bonnie Bermas5, Ali Duarte-Garcia6, Amy Bennett7, Candace Feldman8, Shivani Garg9, Leah Haseley10, Shraddha Jatwani11, Tracy Johansson12, Alex Limanni13, Wambui Machua14, Wendy Rodgers15, Brad Rovin16, Yesenia Santiago-Casas17, Lisa Suter18, JoAnn Zell19, Patti Katz20 and Christie M. Bartels21, 1University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 2Massachusetts General Hospital, Boston, MA, 3University of Calgary, Calgary, AB, Canada, 4Vanderbilt University Medical Center, Nashville, TN, 5UT Southwestern, Dallas, TX, 6Mayo Clinic, Rochester, MN, 7ACR, Atlanta, GA, 8Brigham and Women's Hospital, Boston, MA, 9Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 10University of Washington, Seattle, WA, 11Dignity Health-MMG Rheumatology, East Norriton, PA, 12American College of Rheumatology, Atlanta, GA, 13Self, Dallas, TX, 14Piedmont Healthcare, Atlanta, GA, 15Lupus Foundation of America, Los Angeles, CA, 16Ohio State University, Columbus, OH, 17Guillermo Valenzuela MD PA, Plantation, FL, 18Yale School of Medicine, New Haven, CT, 19University of Colorado Anschutz Medical Campus, Denver, CO, 20University of California San Francisco, San Rafael, CA, 21University of Wisconsin, School of Medicine and Public Health, Madison, WI

Meeting: ACR Convergence 2023

Keywords: Quality Indicators, quality of care, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1895–1912) Measures & Measurement of Healthcare Quality Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Collaborating with the Centers for Disease Control and Prevention (CDC), the ACR has developed new quality measures for lupus clinical care, including clinical and patient-reported outcome measures (PROMs), through a consensus-based process. Here we summarize the development of the 5 measures and introduce corresponding Healthy People with Lupus 2030 goals, which aim to guide the widespread adoption of these measures.

Methods: Two interdisciplinary workgroups, one focused on clinical process-of-care measures and one focused on PROMs, were convened. Both groups used literature reviews, modified Delphi procedures, and extensive patient input to arrive at lupus quality measures. For clinical measures, workgroup members extracted quality constructs from guidelines and rated them by importance and feasibility to generate evidence-based quality measure statements. In 3 Delphi sessions, a multidisciplinary panel voted on the importance to individual patients, feasibility of measurement, and public health impact of each statement. Measures with consensus on feasibility and importance were ranked to identify the top three. For PROMs, experts reviewed literature regarding quality-of-life domains in lupus and conducted focus groups with patients to prioritize domains and measures. A Delphi panel reviewed PROMs corresponding to priority domains for content validity, psychometric quality, feasibility of implementation, and importance for guiding patient-self management. The patient advisory panel reviewed PROMs in parallel and contributed to selecting final measures. Healthy People with Lupus 2030 goals were derived from the final clinical and PRO-based measures.

Results: For clinical process-of-care measures, review of guidelines and distillation of 57 quality constructs resulted in 15 quality measure statements. The 3 most highly ranked quality measures were 1) increasing hydroxychloroquine use, 2) avoiding glucocorticoid use >7.5 mg/day for >6 months, and 3) monitoring of kidney function and urine protein excretion at least every 6 months. For PROMs, literature review identified 12 domains. The workgroup and patient partners ranked depression, physical function, pain, cognition, and fatigue as high-priority domains. Delphi panel members and patient advisors recommended the 2 highest rated domains, physical function and depression, for annual measurement. PROMs recommended for depression were the Patient Health Questionnaire (PHQ) or Patient Reported Outcomes Measurement Information System (PROMIS) depression scales; PROMs recommended for physical function were the PROMIS physical function scales or the Multi-Dimensional Health Assessment Questionnaire (MDHAQ). The Table shows the final measures and corresponding Healthy People with Lupus 2030 goals.

Conclusion: Healthy People with Lupus 2030 provides a vision for improving clinical care for all people with lupus in the United States (Figure). Key priorities are increasing the use of hydroxychloroquine, reducing glucocorticoid exposure, regular monitoring for lupus nephritis (to prevent loss to follow-up and kidney failure), reducing disability, and reducing depression and suicide among people with lupus.

Supporting image 1

Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States

Supporting image 2

Healthy People with Lupus 2030 Campaign


Disclosures: J. Yazdany: AstraZeneca, 2, 5, Aurinia, 5, Gilead, 5, Pfizer, 2; A. Jorge: None; C. Barber: None; A. Barnado: None; B. Bermas: None; A. Duarte-Garcia: None; A. Bennett: None; C. Feldman: BMS Foundation, 5, Curio Bioscience, 12, My husband is one of the founders and will receive equity (but has not received anything to date)., OM1, Inc., 2, Pfizer, 5; S. Garg: None; L. Haseley: None; S. Jatwani: None; T. Johansson: None; A. Limanni: None; W. Machua: None; W. Rodgers: None; B. Rovin: AstraZeneca, 2, 5, Aurinia, 2, 5, Biogen, 2, F. Hoffmann-La Roche Ltd, 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2; Y. Santiago-Casas: None; L. Suter: Centers for Medicare Medicaid Services, 12, Salary support from unrelated CMS ontract, unrelated NIH grant to Elena Losina/BWH, 1; J. Zell: None; P. Katz: None; C. Bartels: Pfizer, 5.

To cite this abstract in AMA style:

Yazdany J, Jorge A, Barber C, Barnado A, Bermas B, Duarte-Garcia A, Bennett A, Feldman C, Garg S, Haseley L, Jatwani S, Johansson T, Limanni A, Machua W, Rodgers W, Rovin B, Santiago-Casas Y, Suter L, Zell J, Katz P, Bartels C. Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/healthy-people-with-lupus-2030-goals-to-improve-the-quality-of-care-and-health-of-all-people-with-lupus-in-the-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/healthy-people-with-lupus-2030-goals-to-improve-the-quality-of-care-and-health-of-all-people-with-lupus-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology